0.794

5.63% +0.0423

Hookipa Pharma Inc (HOOK)

Overview News Price History Option Chain Financials Discussions Forecast

Hookipa Pharma Inc stock is currently priced at $0.794, with a 24-hour trading volume of 313.95K. It has seen a +5.63% increased in the last 24 hours and a -10.52% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7506 pivot point. If it approaches the $0.8111 resistance level, significant changes may occur.

Previous Close:

$0.7517

Open:

$0.7666

24h Volume:

313.95K

Market Cap:

$78.57M

Revenue:

$20.55M

Net Income/Loss:

$-69.07M

P/E Ratio:

-0.8725

EPS:

-0.91

Net Cash Flow:

$-37.50M

1W Performance:

-0.75%

1M Performance:

-10.52%

6M Performance:

+39.54%

1Y Performance:

-39.39%

1D Range:

$0.7666

$0.8039

52W Range:

$0.41

$1.29

Hookipa Pharma Inc Stock (HOOK) Company Profile

Name

Hookipa Pharma Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

431 890 6360

Address

350 Fifth Avenue, 72nd Floor Suite 7240, New York, NY

Employee

131

Twitter

@HookipaPharma

Next Earnings Date

2024-06-17

Latest SEC Filings

HOOK's Discussions on Twitter

Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-22	Downgrade	BofA Securities	Buy → Underperform
Nov-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-08-21	Initiated	Morgan Stanley	Overweight
Nov-03-20	Initiated	Truist	Buy
Oct-26-20	Initiated	JMP Securities	Mkt Outperform
Oct-19-20	Resumed	H.C. Wainwright	Buy
Sep-27-19	Initiated	H.C. Wainwright	Buy
May-13-19	Initiated	BofA/Merrill	Buy
May-13-19	Initiated	RBC Capital Mkts	Outperform

View All

Hookipa Pharma Inc Stock (HOOK) Latest News

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 ... - GlobeNewswire

GlobeNewswire

Here's What HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shareholder Ownership Structure Looks Like - Yahoo Movies UK

Yahoo Movies UK

Insider Buying: Kandera Reinhard, Hookipa Pharma Inc [HOOK] Chief Financial Officer invested 7000 shares – Knox ... - Knox Daily

Knox Daily

Does Hookipa Pharma Inc (HOOK) offer a good opportunity for investors? – Sete News - SETE News

SETE News

Here's What HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shareholder Ownership Structure Looks Like - Yahoo Movies UK

Yahoo Movies UK

HOOKIPA stock falls 20% in wake of Phase 1/2 study results (NASDAQ:HOOK) - Seeking Alpha

Seeking Alpha

Hookipa Pharma Inc Stock (HOOK) Financials Data

Hookipa Pharma Inc (HOOK) Revenue 2024

HOOK reported a revenue (TTM) of $20.55 million for the quarter ending September 30, 2023, a +99.21% rise year-over-year.

Hookipa Pharma Inc (HOOK) Net Income 2024

HOOK net income (TTM) was -$69.07 million for the quarter ending September 30, 2023, a +6.45% increase year-over-year.

Hookipa Pharma Inc (HOOK) Cash Flow 2024

HOOK recorded a free cash flow (TTM) of -$37.50 million for the quarter ending September 30, 2023, a +32.96% increase year-over-year.

Hookipa Pharma Inc (HOOK) Earnings per Share 2024

HOOK earnings per share (TTM) was -$0.83 for the quarter ending September 30, 2023, a +45.75% growth year-over-year.

Hookipa Pharma Inc Stock (HOOK) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Kandera Reinhard	Chief Financial Officer	Aug 16 '23	Buy	0.71	8,000	5,712	36,092
Aldag Jorn	Chief Executive Officer	Jul 11 '23	Buy	0.83	5,000	4,142	71,952
Aldag Jorn	Chief Executive Officer	Jul 07 '23	Buy	0.81	5,000	4,050	66,952
Aldag Jorn	Chief Executive Officer	Jul 05 '23	Buy	0.89	5,000	4,450	61,952
Aldag Jorn	Chief Executive Officer	Jul 03 '23	Buy	0.89	5,000	4,456	56,952
Kandera Reinhard	Chief Financial Officer	Jun 30 '23	Buy	0.88	12,000	10,560	28,092

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.